<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04096716</url>
  </required_header>
  <id_info>
    <org_study_id>201908018</org_study_id>
    <nct_id>NCT04096716</nct_id>
  </id_info>
  <brief_title>Mapping Draining Lymph Nodes in CNS Malignancies</brief_title>
  <official_title>Mapping Draining Lymph Nodes in CNS Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lloyd J. Old STAR Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine whether the lymph nodes that drain a brain&#xD;
      tumor can be detected by imaging after injection of a substance called Tc-99m tilmanocept&#xD;
      directly into the brain tissue around the tumor. Tc-99m tilmanocept is a radioactive&#xD;
      substance that is used to find lymph nodes by injecting it and then scanning the body with a&#xD;
      device that can trace its radioactivity. In this study, the investigators are looking to see&#xD;
      how long it takes the Tc-99m tilmanocept to travel from the tumor to the lymph nodes. The&#xD;
      investigators will be using it to map lymph nodes as they relate to specific brain areas.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time course of Tc-99m tilmanocept drainage to the lymph nodes from the brain (Cohort 1 only)</measure>
    <time_frame>Up to Day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify and map lymph nodes from distinct brain regions as measured by the 2013 international consensus guidelines for cervical and cranial lymph nodes</measure>
    <time_frame>Up to Day 2</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Central Nervous System Neoplasms</condition>
  <condition>Central Nervous System Tumor</condition>
  <arm_group>
    <arm_group_label>Cohort 1: Tc-99m tilmanocept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor&#xD;
Portable planar imaging will be obtained at 4.5 Â± 2.5 hours and 24 +/- 8 hours after injection of Tc-99m tilmanocept.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2A: Tc-99m tilmanocept frontal lobe injection site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor&#xD;
SPECT/CT of the head and neck will be obtained when practical on the day of surgery.&#xD;
If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2B: Tc-99m tilmanocept parietal lobe injection site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor&#xD;
SPECT/CT of the head and neck will be obtained when practical on the day of surgery.&#xD;
If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2C: Tc-99m tilmanocept temporal lobe injection site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor&#xD;
SPECT/CT of the head and neck will be obtained when practical on the day of surgery.&#xD;
If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2D: Tc-99m tilmanocept occipital lobe injection site</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The surgeon will inject up to 0.5 mL of reconstituted Tc-99m tilmanocept using a blunt tipped needle 1 cm into the wall of the resection cavity after completing surgical resection of the tumor&#xD;
SPECT/CT of the head and neck will be obtained when practical on the day of surgery.&#xD;
If the patient is not sufficiently recovered from surgery to be transported to the Division of Nuclear Medicine for imaging, SPECT/CT will be done on Day 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tc-99m tilmanocept</intervention_name>
    <description>Tc-99m tilmanocept is a radioactive diagnostic agent.</description>
    <arm_group_label>Cohort 1: Tc-99m tilmanocept</arm_group_label>
    <arm_group_label>Cohort 2A: Tc-99m tilmanocept frontal lobe injection site</arm_group_label>
    <arm_group_label>Cohort 2B: Tc-99m tilmanocept parietal lobe injection site</arm_group_label>
    <arm_group_label>Cohort 2C: Tc-99m tilmanocept temporal lobe injection site</arm_group_label>
    <arm_group_label>Cohort 2D: Tc-99m tilmanocept occipital lobe injection site</arm_group_label>
    <other_name>Lymphoseek</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Candidate for surgical resection of suspected brain tumor, including benign tumors&#xD;
             (e.g., meningioma) and malignant tumors (e.g., glioma or metastatic disease).&#xD;
&#xD;
          -  Suitable candidate to receive TC 99m injection and study related imaging post-op per&#xD;
             the PI and/or treating neurosurgeon.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  Willing and able to provide informed consent (or consent of legally authorized&#xD;
             representative).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Documented hypersensitivity to dextran and/or modified forms of dextran.&#xD;
&#xD;
          -  Pregnant.&#xD;
&#xD;
          -  Prior surgical evacuation of lymph nodes of the head and/or neck&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanner Johanns, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tanner Johanns, M.D., Ph.D.</last_name>
    <phone>314-273-2723</phone>
    <email>tannerjohanns@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanner Johanns, M.D., Ph.D.</last_name>
      <phone>314-273-2723</phone>
      <email>tannerjohanns@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Tanner Johanns, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Barry A Siegel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andrew Coxon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rupen Desai, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

